ICCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's beginner level, long-term investment preference, and the current data, IceCure Medical Ltd (ICCM) is not a strong buy at this moment. The stock has shown significant price declines recently, with technical indicators pointing to a bearish trend. While there are some positive developments, such as the FDA approval for ProSense and improved gross margins, the company's financials remain weak, and there are no strong trading signals or influential buying activity to support a buy decision. A hold is recommended for now.
The stock is in a bearish trend with the MACD histogram below zero and negatively expanding. RSI indicates the stock is oversold at 13.111. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 0.442 and S2 at 0.357.
FDA approval for ProSense in low-risk breast cancer.
Appointment of new CFO and plans for new leadership roles.
Revenue growth of 28.40% YoY in Q3 2025.
Significant price drop of -33.66% in the regular market and -28.52% pre-market.
Net income remains negative at -$3,859,000, with a YoY decline of -6.99%.
Bearish technical indicators and lack of strong trading signals.
In Q3 2025, revenue increased by 28.40% YoY to $850,000, gross margin improved to 36.28%, and EPS rose to -0.24 (200% YoY improvement). However, net income remains negative at -$3,859,000, reflecting ongoing financial struggles.
No analyst rating or price target changes provided.
